Welcome to our dedicated page for Senseonics Holdings news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics Holdings stock.
Senseonics Holdings, Inc. (symbol: SENS) is a pioneering medical technology firm based in Germantown, Maryland. The company's primary focus is on developing and commercializing advanced glucose monitoring systems that significantly improve the lives of people managing diabetes. Utilizing cutting-edge fluorescence sensing technology, Senseonics has designed the Eversense Continuous Glucose Monitoring (CGM) System, recognized for being the first fully implantable CGM system. This system comprises a tiny sensor implanted under the skin, an external smart transmitter, and a user-friendly mobile application, allowing for real-time glucose monitoring without the need for a dedicated receiver.
The Eversense CGM System stands out for its accuracy and stability throughout its extended sensor life, offering continuous glucose monitoring for up to 180 days. This long-term solution provides an alternative to traditional short-term CGMs, catering to individuals who require a more stable and reliable glucose monitoring option.
Senseonics has established strong partnerships, including a notable collaboration with Ascensia Diabetes Care, which ensures that their innovative solutions reach a global audience. Their latest product, the Eversense E3 CGM System, is part of an extended assistance program known as the Eversense Payment Assistance and Simple Savings (PASS) Program. This program offers eligible individuals in the U.S. the opportunity to access the Eversense E3 systems at a significantly reduced out-of-pocket cost of $99 for each six-month period, thereby making continuous glucose monitoring more affordable.
Senseonics is committed to advancing diabetes management technology, as evidenced by their continued innovation and dedication to improving accessibility to their products. The company's forward-looking approach and strategic alliances position them as a key player in the medical technology landscape, specifically in the context of diabetes management.
Senseonics (AMEX:SENS) will release its fourth quarter and full year 2022 financial results after market close on March 15, 2023. A joint virtual event with PHC Holdings and Ascensia Diabetes Care will take place on the same day at 6:30 pm ET, featuring presentations from executives including Tim Goodnow and Rick Sullivan. They will discuss the Eversense technology portfolio, commercial partnerships, and provide financial guidance. The webcast will be accessible on Senseonics' website under “Investor Relations” for future reference.
Senseonics Holdings, Inc. (NYSE American: SENS) announced it granted equity to 10 new non-executive employees under its 2019 Inducement Plan. On January 5, 2023, the Compensation Committee awarded non-qualified stock options totaling 115,000 shares at an exercise price of $1.02, reflecting the closing share price on the grant date. The options will vest 25% on the first anniversary of employment and monthly thereafter over three years, contingent on continued service. Senseonics specializes in long-term implantable continuous glucose monitoring systems for diabetes management.
Senseonics Holdings, Inc. (SENS), a leader in long-term implantable continuous glucose monitoring systems, has announced their participation in the Stifel Healthcare Conference in New York, NY. Scheduled for Tuesday, November 15, 2022, at 11:30am ET, management will engage in one-on-one meetings post-presentation. A live and recorded webcast will be accessible through a provided link.
Senseonics aims to enhance the lives of those with diabetes through its innovative glucose management technology, including the Eversense CGM system that continuously transmits glucose data to users' mobile devices.
Senseonics Holdings, Inc. (NYSE American: SENS) reported its financial results for the quarter ended September 30, 2022, generating $4.6 million in revenue, up from $3.5 million in Q3 2021. U.S. revenue rose to $1.9 million, while international revenue saw a decline to $2.7 million. The company experienced a net loss of $60.4 million compared to a net income of $42.9 million in the previous year, largely due to non-cash accounting adjustments. Senseonics updated its full-year revenue outlook to $15.0 million to $17.0 million from a previous range of $14.0 million to $18.0 million.
Senseonics Holdings, Inc. (SENS) announces its collaboration with the Nurse Practitioner Group (NPG) to enhance access to the Eversense® E3 Continuous Glucose Monitoring (CGM) System. The initiative aims to provide convenient at-home and in-office insertion options for diabetes patients. The first Eversense E3 sensor was successfully inserted in Florida, with plans for expansion across the U.S. This partnership will facilitate certified NPG providers to perform Eversense procedures, thereby broadening clinician reach and improving patient experiences.
Senseonics Holdings, Inc. (NYSE American: SENS) has announced it will release its third quarter 2022 financial results after market close on November 8, 2022. The management will host a conference call at 4:30 p.m. ET on the same day to discuss the company's performance. Senseonics focuses on long-term, implantable continuous glucose monitoring (CGM) systems aimed at the diabetes community, with products like Eversense® and Eversense® XL providing real-time glucose data through a small sensor under the skin.
Senseonics Holdings, Inc. (NYSE American: SENS) announced participation in the upcoming Morgan Stanley Global Healthcare Conference in New York. On October 5, 2022, the company granted 6 non-executive employees stock options for a total of 78,000 shares at an exercise price of $1.34, contingent on continued service and vesting after one year. Senseonics aims to expand its Eversense CGM System availability and enhance the product, which continuously measures glucose levels for up to 6 months, providing an alternative to traditional fingerstick tests.
Senseonics Holdings, Inc. (NYSE American: SENS) announced its participation in the Morgan Stanley Global Healthcare Conference on September 13, 2022, at 7:20 am ET in New York, NY. The event will include one-on-one meetings, and interested parties can access a live and recorded webcast via the company's website at www.senseonics.com. Senseonics specializes in long-term, implantable continuous glucose monitoring systems, aiming to enhance the lives of those with diabetes.
Senseonics Holdings, Inc. (AMEX: SENS) announced the transition of its Chief Financial Officer, Nick Tressler, effective September 1, 2022. Rick Sullivan, the current Vice President of Finance, will succeed Tressler. The company emphasizes Sullivan's proven track record and leadership abilities to enhance operational and financial performance. Tressler will remain with Senseonics in a supporting role until the end of the year. The transition is expected to continue the company's strategic initiatives in the medical technology sector, specifically in long-term glucose monitoring systems.
Senseonics Holdings, Inc. (NYSE American: SENS) plans to present at the Inaugural Gilmartin Group Emerging Showcase virtually on August 31, 2022, at 3:00pm ET. The company specializes in developing long-term, implantable continuous glucose monitoring systems for diabetes management. Interested parties can access a live and archived webcast of the presentation on the company’s website at www.senseonics.com. The Eversense® CGM systems provide real-time glucose data through a small sensor under the skin, enhancing diabetes care.
FAQ
What is the current stock price of Senseonics Holdings (SENS)?
What is the market cap of Senseonics Holdings (SENS)?
What does Senseonics Holdings, Inc. specialize in?
What is the Eversense Continuous Glucose Monitoring (CGM) System?
How long can the Eversense CGM System monitor glucose levels?
What is the Eversense Payment Assistance and Simple Savings (PASS) Program?
How does Senseonics' CGM technology benefit people with diabetes?
Where is Senseonics Holdings, Inc. headquartered?
Who are Senseonics' key partners?
How can I learn more about the Eversense CGM System?
Is the Eversense CGM System available outside the United States?
What is the mission of Senseonics Holdings, Inc.?
